Our goal is to serve as a resource for all Canadians affected by aHUS, and form a nationwide community of aHUS patients.
FDA Grants Orphan Drug Designation to Soliris® (eculizumab) for Prevention of Delayed Graft Function (DGF) in Renal Transplant Patients
Alexion Pharmaceuticals Inc. – January 21, 2014
Stay connected with the aHUS community in Canada! To receive info and updates from aHUS Canada, sign up here:
In addition to providing support to patients and caregivers, aHUS Canada strives to connect those affected by the condition to establish a Canadian aHUS community, build public awareness and understanding of this very rare and potentially fatal disease and advocate for the best possible care and treatment for patients.